
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is expected to continue its trend of consistent growth and market share gains in the medical device industry, supported by strong earnings and organic revenue growth in Q1 2026. The company's focus on scale, market share, and operational discipline has resulted in increased profitability, debt reduction, and share repurchases, providing a positive outlook for future performance. However, as with any company, there are potential risks to consider, such as competition and staffing shortages, which should be monitored closely. Overall, GMED's continued expansion into international markets and commitment to product innovation make it a strong buy opportunity with potential for even higher growth in a bull case scenario.
Bears say
Globus Medical is facing several challenges that indicate a negative outlook on its stock. Despite EBITDA margin beating consensus and potential upside drivers such as faster spine market growth and higher Enabling Technologies sales, GMED's revenue growth is slowing, and its margins are expected to remain flat. Additionally, the company faces competitive pressure in its ExcelsiusGPS division, and its acquisitions may not provide sufficient value. Moreover, with the majority of voting power held by Chairman of the Board David Paul, there may be governance concerns for shareholders. Furthermore, our bear case scenario indicates a potential downside for the stock, and it is trading at a high P/E multiple.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares